再鼎醫藥
再鼎醫藥 Zai Lab www.zailaboratory.com
再鼎醫藥是一家致力于研究、開發和銷售創新藥物的制藥企業。再鼎醫藥針對目前尚無良好治療手段的疾病領域開發新藥，以改善全球病人的生活質量。再鼎醫藥通過內部研發和授權許可等方式建立全面的產品線。我們希望公司開發的新藥能夠遏制疾病，并為患者帶來顯著療效。
再鼎醫藥創建于2013年，公司擁有一支在全球制藥企業和研發機構富有經驗的世界級管理團隊。這支擁有卓越成功經驗的創始人團隊被譽為中國快速發展的生物技術產業的先驅，曾帶領多個成品成功獲得中國和美國食品藥品監督管理局的認可。這支團隊最先在中國嘗試新藥快速審批途徑并獲得批準，同時也與多個跨國制藥巨頭建立了長期的戰略合作伙伴關系。在再鼎醫藥，團隊將繼續投身于在中國為世界開發高質量的創新藥。
再鼎醫藥獲得數家生物醫藥領域的全球頂級投資機構的支持，包括啟明創投基金，凱鵬華盈中國基金，紅杉資本和泰福資本。這些投資機構都將堅定地支持再鼎醫藥成長為生物醫藥領域的國際領先企業。
再鼎醫藥 Zai Lab
上海辦公室：
上海市浦東新區
張江高科哈雷路1043號8號樓502, 201203
電話: +86 21 6163 2588
傳真: +86 21 6163 2570
郵箱: BD@zailaboratory.com
Zai Lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. Our vision is to address the largest unmet medical needs and transform patients’ lives around the world. We take a unique approach to combine both in-licensed products and internal R&D to achieve a rich pipeline. We believe our drug candidates can be truly disease modifying and bring significant benefits to patients.
The company was founded in 2013 by a group of industry veterans. The founders are known as pioneers in China’s fast advancing biotech industry with a proven track record for successful Chinese CFDA and US FDA filings and approvals. Our senior management team introduced fast regulatory approval pathways in China and developed a variety of partnership models with multinational pharmaceutical companies. We endeavor to conduct world class clinical development in China and beyond.
Zai Lab has strong backing from a leading group of healthcare investors including Qiming Venture Partners, Kleiner Perkins Caufield & Byers, Sequoia Capital and TF Capital. Our investors are committed to support Zai Lab to become a global biopharmaceutical leader based in China.
